MAIA Biotechnology, Inc.
Climate Impact & Sustainability Data (2022, 2023, 2024)
Reporting Period: 2022
Environmental Metrics
Social Achievements
- We believe that our business benefits from the different perspectives a diverse workforce brings, and we pride ourselves on having a strong, inclusive and positive culture based on our shared mission and values.
Climate Goals & Targets
Short-term Goals:
- assess this approach in a Proof-of-Concept study
Environmental Challenges
- there is substantial doubt regarding our ability to continue as a going concern. We will need substantial additional funding, which may not be available on acceptable terms, or at all.
- earlier development of THIO was not commercially pursued.
- Even if THIO successfully advances through clinical studies and towards approval for use, we may face early competition from generic alternatives to THIO after expiration of any applicable regulatory exclusivities.
Mitigation Strategies
- We expect to continue to incur net losses and negative cash flows for the foreseeable future.
- We plan to approach the FDA to request a modified toxicity requirement to allow us a reduced time and expenditure to IND in the United States, however, the FDA may not grant such request.
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: 2023
Environmental Metrics
Social Achievements
- Maintains satisfactory working relationship with employees; no significant labor disputes or difficulty recruiting staff.
Climate Goals & Targets
Medium-term Goals:
- Initiate Phase 2 clinical trial in multiple solid tumor indications of THIO administered in sequence with Anti-PD-1 or Anti-PD-L1 agents in 2025.
Short-term Goals:
- Seek accelerated approval for THIO in the US for treatment of advanced NSCLC in late 2024.
Environmental Challenges
- Substantial doubt about ability to continue as a going concern due to limited cash reserves and ongoing losses.
- Intense competition in the biopharmaceutical industry.
- Lengthy and uncertain regulatory approval processes.
- Difficulties in patient enrollment and retention for clinical trials.
- Dependence on third-party manufacturers and CROs.
- Risks associated with operating internationally.
- Potential for product liability lawsuits.
- Need for additional capital to fund operations.
Mitigation Strategies
- Seeking additional capital through equity offerings, debt financings, and collaborations.
- Developing a focused sales, distribution, and marketing infrastructure.
- Acquiring product liability insurance.
- Implementing robust internal controls and compliance measures.
- Managing manufacturing relationships with third parties.
- Exploring strategic collaborations to accelerate development and commercialization.